NCT06452212View on ClinicalTrials.gov

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

CompletedOBSERVATIONAL
Enrollment

23

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

July 29, 2024

Study Completion Date

July 29, 2024

Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
OTHER

No Intervention

No investigational drug will be administered to participants in this study.

Trial Locations (1)

Unknown

KR82001, Seoul

All Listed Sponsors
lead

Astellas Pharma Korea, Inc.

INDUSTRY

NCT06452212 - Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients | Biotech Hunter | Biotech Hunter